ing task with five trials and an interference list (15 new words -List B) read to the subject after the fifth trial of List A. The original RAVLT also includes a recognition trial in which subjects are asked to identify List A words from a larger list of words that includes distractor words. In most versions of the RAVLT, the distractor list is comprised of words from List B as well as other words, most having either a semantic and/or a phonetic link with words from Lists A and/or B. The objective of this abstract is to present the translation process of the RAVLT into US Spanish (six pairs of recall lists and six recognition lists). METHODS: For the recall words, a direct translation, in collaboration with a speech therapist and a neuropsychologist, was recommended, with frequency of use similar to the original as well as word length (Ϯ1 syllable or Ϯ2 syllables and Ϯ2 characters). For the recognition words, the translations had to respect the semantic and phonetic links to the recall words. RESULTS: Fifty out of 180 words from the recall lists raised discussions because of difficulties in finding translations with the appropriate word length. Thirty-four out of 120 words from the recognition list proved difficult to translate because of problems in finding direct translations that respected the phonetic or semantic links to the recall words. For instance, the recognition word "Balloon," with a phonetic link with "Moon" (List A #1), was "translated" as "Lona" (Tarp) to keep the phonetic link with "Luna" (Moon). CONCLUSIONS: This methodology enabled production of a US Spanish version of the RAVLT respecting the intent of the original US English. 
SYSTEMIC DISORDERS/CONDITIONS -Clinical Outcomes Studies

PSY1 HOSPITALIZATION COSTS ATTRIBUTABLE TO OBESITY IN PATIENTS WITH ADVERSE DRUG EVENTS IN US HOSPITAL FOR 2001-2009
OBJECTIVES:
To estimate hospitalization costs attributable to obesity (CAO) in patients with adverse drug events (ADE) in the US hospital. METHODS: The study used the Nationwide Inpatient Sample (NIS) of the Healthcare Cost and Utilization Project (HCUP) from 2001 to 2009. The NIS includes sampling weight and design variable for generating national representative estimates. ADE were defined as poisoning due to inappropriate uses or medication errors, and an adverse drug reaction. The cost to charge ratios were applied to estimate hospitalization costs using the hospital charge. The recycled prediction method was employed to estimate CAO. This method estimated parameters by running a generalized linear model with log link function and gamma distribution of hospital costs on all the study variables. CAO was defines as the differences between the predicted mean hospitalization costs for obese patients with ADE and the predicted mean hospitalized costs if obese patients with ADE could be a normal weight patients with ADE. All costs were converted to 2010 US dollars. RESULTS: A total of 2,177,755 admissions due to ADE were identified. Among these admissions, 4.3% of them were obese patients. Obese patients were older than non-obese patients (46.6 vs. 43.7, pϽ0.001) and stayed longer in hospital than non-obese patients (3.4 vs. 2.9 days, respectively). The average hospitalization costs were $9099 (95%CI:$8,926-$9272) for obese and $8014 (95%CI:$7978-$8051) for non-obese patients. Overall, the average CAO in patients with ADE was predicted to be $725 (95%CI:$720-$729) after adjusting for patients characteristics and comorbidities. CAO were increased as patients age increased from $457 (95%CI:$446-$468) for age 0-17 years old to $1,051($993-$1,110) for age Ն85years old. CONCLUSIONS: Obese patients with ADE have significantly higher hospitalization costs compared to non-obese patients with ADE. Since the additional costs due to obesity are avoidable, the additional efforts to lose weight are strongly recommended. 
PSY2 ADVERSE EVENT BURDEN, RESOURCE USE AND COSTS ASSOCIATED WITH IMMUNOSUPPRESSANT THERAPY FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS: A SYSTEMATIC LITERATURE REVIEW
OBJECTIVES:
To quantify the incidence of adverse events (AEs), identify discontinuation rates due to AEs, and determine the cost and resource use associated with AEs from azathioprine (AZA), cyclophosphamide (CYC), mycophenolate mofetil (MMF), methotrexate (MTX), and cyclosporine (CsA) in patients with systemic lupus erythematosus (SLE). METHODS: A systematic review of English-language, MED-LINE-and EMBASE-indexed literature published between January 1980 and September 2011 was conducted using terms related to SLE, AEs, discontinuation, resource use and costs. RESULTS: This review identified 38 publications reporting the burden of AEs related to AZA, CYC, MMF, MTX or CsA. The incidence of AEs ranged from 42.8% to 97.3%. Common AEs included infections, gastrointestinal AEs and amenorrhea. In direct comparisons, AZA was associated with more hematological cytopenias than MMF (26.9% vs. 3.8%, respectively) based on one study. CYC was associated with more infections than MMF (40-77% vs. 12.5-32%, respectively) or AZA (17-77% vs. 11-29%, respectively), and it was also related to more gynecological toxicities than MMF (32-36% vs. 3.6-6%, respectively) or AZA (32-71% vs. 8-18%, respectively). However, other studies reported no difference in AEs associated with CYC compared to either AZA or MMF, or with AZA compared to CsA. Discontinuation rates due to AEs were 0 -17% in short-term randomized controlled trials (RCTs), 2.3-44.4% in long-term RCTs, and 1.9 -21.8% in observational studies. The rate of hospitalized infections was similar between patients taking MMF and AZA (1 day per patient-year in each group), but higher for those taking CYC (10 days per patient-year). No studies reported costs associated with AEs. CONCLUSIONS: The incidence of AEs associated with SLE immunosuppresants was consistently high as reported in the SLE literature, while discontinuation due to these AEs widely varied. Studies describing costs and resource use associated with these AEs were sparse and warrant further study.
